Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT00777101
Registration number
NCT00777101
Ethics application status
Date submitted
21/10/2008
Date registered
22/10/2008
Date last updated
9/08/2018
Titles & IDs
Public title
Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer
Query!
Scientific title
A Phase 2 Randomized Open-Label Study of Neratinib Versus Lapatinib Plus Capecitabine For The Treatment Of ErbB-2 Positive Locally Advanced Or Metastatic Breast Cancer
Query!
Secondary ID [1]
0
0
3144A2-3003 / B1891003
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Advanced Breast Cancer
0
0
Query!
Breast Cancer
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Breast
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Neratinib
Treatment: Drugs - Lapatinib
Treatment: Drugs - Capecitabine
Experimental: Neratinib -
Active Comparator: Lapatinib plus Capecitabine -
Treatment: Drugs: Neratinib
Tablets 240 mg orally once per day until disease progression or unacceptable toxicity
Treatment: Drugs: Lapatinib
Tablets 1250 mg orally once per day until disease progression or unacceptable toxicity.
Treatment: Drugs: Capecitabine
Tablets 2000 mg/m² given orally in two evenly divided daily doses for first 14 days of each 21 day cycle. Given until disease progression or unacceptable toxicity.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Progression Free Survival
Query!
Assessment method [1]
0
0
Progression Free Survival, Measured in Months, for Subjects Randomized. Investigator assessment. The time interval from the date of randomization until the earliest date of progression per Response Evaluation Criteria In Solid Tumors Criteria (RECIST) or death due to any cause. For subjects without death or progression, censorship was at the last valid tumor assessment.
Query!
Timepoint [1]
0
0
From randomization date to progression or death, assessed up to 69 months
Query!
Secondary outcome [1]
0
0
Overall Survival (OS)
Query!
Assessment method [1]
0
0
Overall Survival (OS) was defined as the time from randomization to death due to any cause. Subjects last known to be alive were censored at the last date of last contact or the data cutoff employed for the analysis, whichever was earlier.
Query!
Timepoint [1]
0
0
From randomization date to death, assessed up to 69 months
Query!
Secondary outcome [2]
0
0
Objective Response Rate (ORR).
Query!
Assessment method [2]
0
0
Objective Response Rate, investigator assessment. The ORR was defined as the percentage of participants demonstrating a confirmed objective response, either Complete Response (CR) or Partial Response (PR) during the study per Response Evaluation Criteria In Solid Tumors Criteria (RECIST) v.1.0: Complete Response (CR), disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; and Non-PD for non-target lesions, and no new lesions.
Query!
Timepoint [2]
0
0
From randomization date to progression or last tumor assessment, assessed up to 69 months
Query!
Secondary outcome [3]
0
0
Clinical Benefit Rate
Query!
Assessment method [3]
0
0
Clinical benefit rate (CR, PR, or SD = 24 weeks) for women For ErbB2 Positive Advanced Breast Cancer. Clinical benefit rate was the percentage of subjects who achieved overall tumor response per Response Evaluation Criteria In Solid Tumors Criteria (RECIST) v1.0: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Stable Disease (SD), Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.
Clinical Benefit (CB) = CR + PR + SD >= 24 weeks.
Query!
Timepoint [3]
0
0
From randomization date to progression or last tumor assessment, assessed up to 69 months
Query!
Secondary outcome [4]
0
0
Duration of Response
Query!
Assessment method [4]
0
0
Duration of response was measured from the time at which response criteria were met for complete response (CR) or partial response (PR) (whichever status was recorded first) until the first date of recurrence or progressive disease (PD) or death. For subjects without death or progression, censorship was at the last valid tumor assessment per Response Evaluation Criteria In Solid Tumors Criteria (RECIST) v1.0: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions.
Query!
Timepoint [4]
0
0
From start date of response to first PD, assessed up to 69 months after the first subject was randomized.
Query!
Secondary outcome [5]
0
0
Frequency of CNS Metastases (Frequency)
Query!
Assessment method [5]
0
0
The percent of patients with symptomatic or progressive CNS lesions was the proportion of subjects who had PD considering CNS lesions only, according to RECIST criteria.
Query!
Timepoint [5]
0
0
From randomization date to first CNS symptom or lesions
Query!
Secondary outcome [6]
0
0
Time to CNS Metastases
Query!
Assessment method [6]
0
0
Time to symptomatic or progressive Central nervous system (CNS) lesions. Time to symptomatic or progressive CNS lesions was the time from the date of randomization until the date of progressive disease (PD) considering CNS lesions only (ie, appearance of newly diagnosed CNS lesions or progressive CNS lesions).
Query!
Timepoint [6]
0
0
From randomization date to first CNS symptom or lesions
Query!
Eligibility
Key inclusion criteria
- Stage IIIB, IIIC, or IV erbB2 (HER2) positive breast cancer
- Prior use of Herceptin (trastuzumab), and a taxane
- Adequate cardiac and renal function
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- More than 2 prior Herceptin (trastuzumab) regimens or prior use of Xeloda
(capecitabine) and / or Tykerb (lapatinib) [Tyverb]
- Bone as the only site of disease
- Active central nervous system metastases (subjects should be stable and off
anticonvulsants and steroids)
- Significant gastrointestinal disorder with diarrhea as major symptom
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
4/02/2009
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
3/06/2018
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
233
Query!
Recruitment in Australia
Recruitment state(s)
QLD,SA,VIC
Query!
Recruitment hospital [1]
0
0
Mater Private Centre for HOCA - South Brisbane
Query!
Recruitment hospital [2]
0
0
Medical Oncology Royal Adelaide Hospital - Adelaide
Query!
Recruitment hospital [3]
0
0
Western Hospital - Footscray
Query!
Recruitment hospital [4]
0
0
Mount Hospital - West Perth
Query!
Recruitment postcode(s) [1]
0
0
4101 - South Brisbane
Query!
Recruitment postcode(s) [2]
0
0
5000 - Adelaide
Query!
Recruitment postcode(s) [3]
0
0
3011 - Footscray
Query!
Recruitment postcode(s) [4]
0
0
6000 - West Perth
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arizona
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Colorado
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Connecticut
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Florida
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Illinois
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Indiana
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Kentucky
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Missouri
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
New York
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Ohio
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Oklahoma
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Oregon
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Pennsylvania
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Tennessee
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Texas
Query!
Country [17]
0
0
Austria
Query!
State/province [17]
0
0
Wien
Query!
Country [18]
0
0
Belgium
Query!
State/province [18]
0
0
Brussels
Query!
Country [19]
0
0
Bulgaria
Query!
State/province [19]
0
0
Sofia
Query!
Country [20]
0
0
Bulgaria
Query!
State/province [20]
0
0
Varna
Query!
Country [21]
0
0
Canada
Query!
State/province [21]
0
0
British Columbia
Query!
Country [22]
0
0
Canada
Query!
State/province [22]
0
0
Quebec
Query!
Country [23]
0
0
Croatia
Query!
State/province [23]
0
0
Varazdin
Query!
Country [24]
0
0
Croatia
Query!
State/province [24]
0
0
Zagreb
Query!
Country [25]
0
0
Czechia
Query!
State/province [25]
0
0
Olomouc
Query!
Country [26]
0
0
France
Query!
State/province [26]
0
0
Lille
Query!
Country [27]
0
0
France
Query!
State/province [27]
0
0
Pierre Benite
Query!
Country [28]
0
0
France
Query!
State/province [28]
0
0
Poitiers
Query!
Country [29]
0
0
France
Query!
State/province [29]
0
0
Villejuif
Query!
Country [30]
0
0
Germany
Query!
State/province [30]
0
0
Hamburg
Query!
Country [31]
0
0
Germany
Query!
State/province [31]
0
0
Heidelberg
Query!
Country [32]
0
0
Greece
Query!
State/province [32]
0
0
Thessaloníki
Query!
Country [33]
0
0
Hong Kong
Query!
State/province [33]
0
0
Hong Kong
Query!
Country [34]
0
0
Hungary
Query!
State/province [34]
0
0
Budapest
Query!
Country [35]
0
0
Hungary
Query!
State/province [35]
0
0
Kecskemet
Query!
Country [36]
0
0
Hungary
Query!
State/province [36]
0
0
Nyiregyhaza
Query!
Country [37]
0
0
Hungary
Query!
State/province [37]
0
0
Szeged
Query!
Country [38]
0
0
Hungary
Query!
State/province [38]
0
0
Veszprem
Query!
Country [39]
0
0
Italy
Query!
State/province [39]
0
0
Prato
Query!
Country [40]
0
0
Italy
Query!
State/province [40]
0
0
Roma
Query!
Country [41]
0
0
Japan
Query!
State/province [41]
0
0
Hokkaido
Query!
Country [42]
0
0
Japan
Query!
State/province [42]
0
0
Tokyo
Query!
Country [43]
0
0
Japan
Query!
State/province [43]
0
0
Aichi
Query!
Country [44]
0
0
Japan
Query!
State/province [44]
0
0
Chiba
Query!
Country [45]
0
0
Japan
Query!
State/province [45]
0
0
Fukuoka
Query!
Country [46]
0
0
Japan
Query!
State/province [46]
0
0
Hiroshima
Query!
Country [47]
0
0
Japan
Query!
State/province [47]
0
0
Hyogo
Query!
Country [48]
0
0
Japan
Query!
State/province [48]
0
0
Kagoshima
Query!
Country [49]
0
0
Japan
Query!
State/province [49]
0
0
Kanagawa
Query!
Country [50]
0
0
Japan
Query!
State/province [50]
0
0
Kumamoto
Query!
Country [51]
0
0
Japan
Query!
State/province [51]
0
0
Kyoto
Query!
Country [52]
0
0
Japan
Query!
State/province [52]
0
0
Niigata
Query!
Country [53]
0
0
Japan
Query!
State/province [53]
0
0
Osaka
Query!
Country [54]
0
0
Japan
Query!
State/province [54]
0
0
Saitama
Query!
Country [55]
0
0
Japan
Query!
State/province [55]
0
0
Shizuoka
Query!
Country [56]
0
0
Japan
Query!
State/province [56]
0
0
Tochigi
Query!
Country [57]
0
0
Jordan
Query!
State/province [57]
0
0
Amman
Query!
Country [58]
0
0
Korea, Republic of
Query!
State/province [58]
0
0
Gyeonggi-do
Query!
Country [59]
0
0
Korea, Republic of
Query!
State/province [59]
0
0
Korea
Query!
Country [60]
0
0
Korea, Republic of
Query!
State/province [60]
0
0
Seoul
Query!
Country [61]
0
0
Mexico
Query!
State/province [61]
0
0
Nuevo Leon
Query!
Country [62]
0
0
Poland
Query!
State/province [62]
0
0
Bialystok
Query!
Country [63]
0
0
Poland
Query!
State/province [63]
0
0
Gdansk
Query!
Country [64]
0
0
Poland
Query!
State/province [64]
0
0
Krakow
Query!
Country [65]
0
0
Poland
Query!
State/province [65]
0
0
Lublin
Query!
Country [66]
0
0
Puerto Rico
Query!
State/province [66]
0
0
San Juan
Query!
Country [67]
0
0
Romania
Query!
State/province [67]
0
0
Bucuresti
Query!
Country [68]
0
0
Romania
Query!
State/province [68]
0
0
Iasi
Query!
Country [69]
0
0
Romania
Query!
State/province [69]
0
0
Sibiu
Query!
Country [70]
0
0
Russian Federation
Query!
State/province [70]
0
0
Saint Petersburg
Query!
Country [71]
0
0
Russian Federation
Query!
State/province [71]
0
0
Moscow
Query!
Country [72]
0
0
Russian Federation
Query!
State/province [72]
0
0
Perm
Query!
Country [73]
0
0
Russian Federation
Query!
State/province [73]
0
0
Ryazan
Query!
Country [74]
0
0
Russian Federation
Query!
State/province [74]
0
0
Sochi
Query!
Country [75]
0
0
Russian Federation
Query!
State/province [75]
0
0
Ufa
Query!
Country [76]
0
0
Serbia
Query!
State/province [76]
0
0
Belgrade
Query!
Country [77]
0
0
Singapore
Query!
State/province [77]
0
0
Singapore
Query!
Country [78]
0
0
Slovenia
Query!
State/province [78]
0
0
Ljubljana
Query!
Country [79]
0
0
South Africa
Query!
State/province [79]
0
0
Gauteng
Query!
Country [80]
0
0
South Africa
Query!
State/province [80]
0
0
KwaZulu Natal
Query!
Country [81]
0
0
South Africa
Query!
State/province [81]
0
0
Western Cape Province
Query!
Country [82]
0
0
Spain
Query!
State/province [82]
0
0
Asturias
Query!
Country [83]
0
0
Spain
Query!
State/province [83]
0
0
Barcelona
Query!
Country [84]
0
0
Spain
Query!
State/province [84]
0
0
A Coruña
Query!
Country [85]
0
0
Spain
Query!
State/province [85]
0
0
Alicante
Query!
Country [86]
0
0
Spain
Query!
State/province [86]
0
0
Caceres
Query!
Country [87]
0
0
Spain
Query!
State/province [87]
0
0
Cordoba
Query!
Country [88]
0
0
Spain
Query!
State/province [88]
0
0
Gerona
Query!
Country [89]
0
0
Spain
Query!
State/province [89]
0
0
Jaen
Query!
Country [90]
0
0
Spain
Query!
State/province [90]
0
0
Madrid
Query!
Country [91]
0
0
Spain
Query!
State/province [91]
0
0
Valencia
Query!
Country [92]
0
0
Spain
Query!
State/province [92]
0
0
Zaragoza
Query!
Country [93]
0
0
Switzerland
Query!
State/province [93]
0
0
Lausanne
Query!
Country [94]
0
0
Switzerland
Query!
State/province [94]
0
0
Winterthur
Query!
Country [95]
0
0
Switzerland
Query!
State/province [95]
0
0
Zuerich
Query!
Country [96]
0
0
Taiwan
Query!
State/province [96]
0
0
Taipei
Query!
Country [97]
0
0
Thailand
Query!
State/province [97]
0
0
Bangkok
Query!
Country [98]
0
0
United Kingdom
Query!
State/province [98]
0
0
Essex
Query!
Country [99]
0
0
United Kingdom
Query!
State/province [99]
0
0
London
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Puma Biotechnology, Inc.
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This is a study of an experimental drug (neratinib) versus a combination of drugs (lapatinib
and capecitabine) in women who have erbB-2 (HER-2) positive metastatic or locally advanced
breast cancer. The goal of this study is to compare the two regimens in shrinking tumors and
extending the lives of women with erbB2 (HER2) positive breast cancer. The study will also
compare the safety of the two regimens and to compare quality of life of patients taking the
two regimens.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT00777101
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Puma
Query!
Address
0
0
Biotechnology
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT00777101
Download to PDF